Review




Structured Review

STEMCELL Technologies Inc anti-human cd38 antibody, clone at-1, fitc
Anti Human Cd38 Antibody, Clone At 1, Fitc, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-human cd38 antibody, clone at-1, fitc/product/STEMCELL Technologies Inc
Average 90 stars, based on 1 article reviews
anti-human cd38 antibody, clone at-1, fitc - by Bioz Stars, 2026-03
90/100 stars

Images



Similar Products

95
Miltenyi Biotec cd38 fitc
Cd38 Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd38 fitc/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
cd38 fitc - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

94
Miltenyi Biotec igg1 fitc cd38 miltenyi biotec
Igg1 Fitc Cd38 Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/igg1 fitc cd38 miltenyi biotec/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
igg1 fitc cd38 miltenyi biotec - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

90
Thermo Fisher anti-human cd38-fitc hb7
Anti Human Cd38 Fitc Hb7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-human cd38-fitc hb7/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
anti-human cd38-fitc hb7 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

94
Miltenyi Biotec cd20 fitc
Cd20 Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd20 fitc/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
cd20 fitc - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

90
Thermo Fisher fitc-anti-cd38
Addition of fucose to the cell culture medium affected the production of cytokines, ATP and Ca 2+ levels, and surface and intracellular expression of <t>CD38</t> of peritoneal macrophages derived from C57BL/6 and Muc2 −/− mice. ( A ). Inflammatory cytokine levels in cell culture medium of peritoneal macrophages from the two mouse strains with and without the addition of 0.1% L-fucose; the median, min, and max for each cytokine is presented in pg/mg protein. ( B ). ATP levels in the peritoneal macrophages of two mouse strains incubated with and without 0.1% L-fucose. ( C ). Ca 2+ levels in the peritoneal macrophages of the two mouse strains incubated with and without 0.1% L-fucose. ( D ). Percentage of peritoneal macrophages with surface CD38 expression from the two mouse strains incubated with and without 0.1% L-fucose. ( E ). Percentage of peritoneal macrophages with intracellular CD38 expression from the two mouse strains incubated with and without 0.1% L-fucose. “C57BL/6” vs. “ Muc2 −/− “ and “with 0.1% L-fucose” vs. “without 0.1% L-fucose”: * p < 0.05, ** p < 0.01, and *** p < 0.001. Two-way PERMANOVA test.
Fitc Anti Cd38, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fitc-anti-cd38/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
fitc-anti-cd38 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc anti-human cd38 antibody, clone at-1, fitc
Addition of fucose to the cell culture medium affected the production of cytokines, ATP and Ca 2+ levels, and surface and intracellular expression of <t>CD38</t> of peritoneal macrophages derived from C57BL/6 and Muc2 −/− mice. ( A ). Inflammatory cytokine levels in cell culture medium of peritoneal macrophages from the two mouse strains with and without the addition of 0.1% L-fucose; the median, min, and max for each cytokine is presented in pg/mg protein. ( B ). ATP levels in the peritoneal macrophages of two mouse strains incubated with and without 0.1% L-fucose. ( C ). Ca 2+ levels in the peritoneal macrophages of the two mouse strains incubated with and without 0.1% L-fucose. ( D ). Percentage of peritoneal macrophages with surface CD38 expression from the two mouse strains incubated with and without 0.1% L-fucose. ( E ). Percentage of peritoneal macrophages with intracellular CD38 expression from the two mouse strains incubated with and without 0.1% L-fucose. “C57BL/6” vs. “ Muc2 −/− “ and “with 0.1% L-fucose” vs. “without 0.1% L-fucose”: * p < 0.05, ** p < 0.01, and *** p < 0.001. Two-way PERMANOVA test.
Anti Human Cd38 Antibody, Clone At 1, Fitc, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-human cd38 antibody, clone at-1, fitc/product/STEMCELL Technologies Inc
Average 90 stars, based on 1 article reviews
anti-human cd38 antibody, clone at-1, fitc - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Thermo Fisher anti-human cd38 fitc clone: hb7
α-CD99-A192 increases expression of activation marker <t>CD38</t> but does not affect T cell major phenotypes. Flow cytometry panels of control (untreated and A192), and α-CD99-A192 treated PBMCs for A, CD3 , B, CD4 , C, CD8 and D, CD25. Flow cytometry panels of control (untreated and A192), and α-CD99-A192 treated expanded T cells for E, CD3 , F, CD4 , G, CD8 and H, CD25. I, Quantified percentage levels of CD3, CD4, CD8 and CD25 untreated, A192 treated, and α-CD99-A192 treated PBMCs. J, Quantified percentage levels of CD3, CD4, CD8 and CD25 untreated, A192 treated, and α-CD99-A192 treated T cells. K, Flow cytometry panel of CD3 + CD69 + cells (Q2) for control A192 treated T cells and α-CD99-A192 treated T cells. L, Flow cytometry panel of CD3 + CD38 + cells (Q2) for control A192 treated T cells and α-CD99-A192 treated T cells. M, Percentage of CD69 + for A192 and α-CD99-A192 treated t cells where no significant change is observed in the α-CD99-A192 treated T cells compared with the control. N, Percentage of CD38 + for A192 and α-CD99-A192 treated T cells where a significant increase is observed in the α-CD99-A192 treated T cells compared with the control. The differences between the groups were analyzed using unpaired t tests (**,P<0.01; *,P<0.05). The experiments were performed utilizing samples obtained from three donors for T cell phenotyping and five donors for CD69 and CD38 activation marker analysis. The T cells utilized in these experiments were expanded using PHA and IL2 from the PBMCs obtained from healthy donors.
Anti Human Cd38 Fitc Clone: Hb7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-human cd38 fitc clone: hb7/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
anti-human cd38 fitc clone: hb7 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

93
Caprico Biotechnologies anti cd38 fitc clone okt10
Monkey ex - vivo -differentiated PC subset classification and differential expression analysis for PCs (A) Dot plot visualization of ex - vivo -differentiated PCs: subsets are listed on the y axis and genes (features) are listed along the x axis. Dot size represents the percentage of cells in a group expressing each gene; dot color indicates the normalized mean expression level in a group. (B) Heatmap showing expression of representative genes of PC markers ( <t>CD38</t> , JCHAIN , XBP1 ) and proliferating marker ( MKI67 ). (C) Cluster renamed to B cell subsets based on the gene features from (A) and (B).
Anti Cd38 Fitc Clone Okt10, supplied by Caprico Biotechnologies, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd38 fitc clone okt10/product/Caprico Biotechnologies
Average 93 stars, based on 1 article reviews
anti cd38 fitc clone okt10 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

90
Caprico Biotechnologies antibodies anti-cd38 fitc clone: okt10
Monkey ex - vivo -differentiated PC subset classification and differential expression analysis for PCs (A) Dot plot visualization of ex - vivo -differentiated PCs: subsets are listed on the y axis and genes (features) are listed along the x axis. Dot size represents the percentage of cells in a group expressing each gene; dot color indicates the normalized mean expression level in a group. (B) Heatmap showing expression of representative genes of PC markers ( <t>CD38</t> , JCHAIN , XBP1 ) and proliferating marker ( MKI67 ). (C) Cluster renamed to B cell subsets based on the gene features from (A) and (B).
Antibodies Anti Cd38 Fitc Clone: Okt10, supplied by Caprico Biotechnologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies anti-cd38 fitc clone: okt10/product/Caprico Biotechnologies
Average 90 stars, based on 1 article reviews
antibodies anti-cd38 fitc clone: okt10 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Addition of fucose to the cell culture medium affected the production of cytokines, ATP and Ca 2+ levels, and surface and intracellular expression of CD38 of peritoneal macrophages derived from C57BL/6 and Muc2 −/− mice. ( A ). Inflammatory cytokine levels in cell culture medium of peritoneal macrophages from the two mouse strains with and without the addition of 0.1% L-fucose; the median, min, and max for each cytokine is presented in pg/mg protein. ( B ). ATP levels in the peritoneal macrophages of two mouse strains incubated with and without 0.1% L-fucose. ( C ). Ca 2+ levels in the peritoneal macrophages of the two mouse strains incubated with and without 0.1% L-fucose. ( D ). Percentage of peritoneal macrophages with surface CD38 expression from the two mouse strains incubated with and without 0.1% L-fucose. ( E ). Percentage of peritoneal macrophages with intracellular CD38 expression from the two mouse strains incubated with and without 0.1% L-fucose. “C57BL/6” vs. “ Muc2 −/− “ and “with 0.1% L-fucose” vs. “without 0.1% L-fucose”: * p < 0.05, ** p < 0.01, and *** p < 0.001. Two-way PERMANOVA test.

Journal: International Journal of Molecular Sciences

Article Title: Changes in the Phenotype and Metabolism of Peritoneal Macrophages in Mucin-2 Knockout Mice and Partial Restoration of Their Functions In Vitro After L-Fucose Treatment

doi: 10.3390/ijms26010013

Figure Lengend Snippet: Addition of fucose to the cell culture medium affected the production of cytokines, ATP and Ca 2+ levels, and surface and intracellular expression of CD38 of peritoneal macrophages derived from C57BL/6 and Muc2 −/− mice. ( A ). Inflammatory cytokine levels in cell culture medium of peritoneal macrophages from the two mouse strains with and without the addition of 0.1% L-fucose; the median, min, and max for each cytokine is presented in pg/mg protein. ( B ). ATP levels in the peritoneal macrophages of two mouse strains incubated with and without 0.1% L-fucose. ( C ). Ca 2+ levels in the peritoneal macrophages of the two mouse strains incubated with and without 0.1% L-fucose. ( D ). Percentage of peritoneal macrophages with surface CD38 expression from the two mouse strains incubated with and without 0.1% L-fucose. ( E ). Percentage of peritoneal macrophages with intracellular CD38 expression from the two mouse strains incubated with and without 0.1% L-fucose. “C57BL/6” vs. “ Muc2 −/− “ and “with 0.1% L-fucose” vs. “without 0.1% L-fucose”: * p < 0.05, ** p < 0.01, and *** p < 0.001. Two-way PERMANOVA test.

Article Snippet: After centrifugation, the cells were resuspended in 100 μL of permeabilization buffer and incubated with Pacific Blue–anti-CD45 (BioLegend, San Diego, CA, USA, Rat IgG2b, k, clone S18009F), PE-anti-CD11b (BioLegend, USA, Rat IgG2b, k, clone M1/70), and FITC-anti-CD38 (Invitrogen, Waltham, MA, USA, clone 90) for 60 min at 4 °C in the dark.

Techniques: Cell Culture, Expressing, Derivative Assay, Incubation

α-CD99-A192 increases expression of activation marker CD38 but does not affect T cell major phenotypes. Flow cytometry panels of control (untreated and A192), and α-CD99-A192 treated PBMCs for A, CD3 , B, CD4 , C, CD8 and D, CD25. Flow cytometry panels of control (untreated and A192), and α-CD99-A192 treated expanded T cells for E, CD3 , F, CD4 , G, CD8 and H, CD25. I, Quantified percentage levels of CD3, CD4, CD8 and CD25 untreated, A192 treated, and α-CD99-A192 treated PBMCs. J, Quantified percentage levels of CD3, CD4, CD8 and CD25 untreated, A192 treated, and α-CD99-A192 treated T cells. K, Flow cytometry panel of CD3 + CD69 + cells (Q2) for control A192 treated T cells and α-CD99-A192 treated T cells. L, Flow cytometry panel of CD3 + CD38 + cells (Q2) for control A192 treated T cells and α-CD99-A192 treated T cells. M, Percentage of CD69 + for A192 and α-CD99-A192 treated t cells where no significant change is observed in the α-CD99-A192 treated T cells compared with the control. N, Percentage of CD38 + for A192 and α-CD99-A192 treated T cells where a significant increase is observed in the α-CD99-A192 treated T cells compared with the control. The differences between the groups were analyzed using unpaired t tests (**,P<0.01; *,P<0.05). The experiments were performed utilizing samples obtained from three donors for T cell phenotyping and five donors for CD69 and CD38 activation marker analysis. The T cells utilized in these experiments were expanded using PHA and IL2 from the PBMCs obtained from healthy donors.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Enhanced T cell activation and cytotoxicity against AML via targeted anti-CD99 nanoparticle treatment

doi: 10.1016/j.biopha.2024.117265

Figure Lengend Snippet: α-CD99-A192 increases expression of activation marker CD38 but does not affect T cell major phenotypes. Flow cytometry panels of control (untreated and A192), and α-CD99-A192 treated PBMCs for A, CD3 , B, CD4 , C, CD8 and D, CD25. Flow cytometry panels of control (untreated and A192), and α-CD99-A192 treated expanded T cells for E, CD3 , F, CD4 , G, CD8 and H, CD25. I, Quantified percentage levels of CD3, CD4, CD8 and CD25 untreated, A192 treated, and α-CD99-A192 treated PBMCs. J, Quantified percentage levels of CD3, CD4, CD8 and CD25 untreated, A192 treated, and α-CD99-A192 treated T cells. K, Flow cytometry panel of CD3 + CD69 + cells (Q2) for control A192 treated T cells and α-CD99-A192 treated T cells. L, Flow cytometry panel of CD3 + CD38 + cells (Q2) for control A192 treated T cells and α-CD99-A192 treated T cells. M, Percentage of CD69 + for A192 and α-CD99-A192 treated t cells where no significant change is observed in the α-CD99-A192 treated T cells compared with the control. N, Percentage of CD38 + for A192 and α-CD99-A192 treated T cells where a significant increase is observed in the α-CD99-A192 treated T cells compared with the control. The differences between the groups were analyzed using unpaired t tests (**,P<0.01; *,P<0.05). The experiments were performed utilizing samples obtained from three donors for T cell phenotyping and five donors for CD69 and CD38 activation marker analysis. The T cells utilized in these experiments were expanded using PHA and IL2 from the PBMCs obtained from healthy donors.

Article Snippet: Anti-Human CD3 PerCP-Cyanine 5.5 (Clone: OKT3; eBioscience, Cat#45–0037–42), Anti-Human CD38 FITC (Clone: HB7; eBioscience, Cat#11–0388) and Anti-Human CD69 PE (Clone: FN50; eBioscience, Cat#12–0699) was added to the cells.

Techniques: Expressing, Activation Assay, Marker, Flow Cytometry, Control

α-CD99-A192 treated T cells show increased cytotoxicity against leukemic cells. Flow cytometry panels showing. A, Annexin V positive cells at 18 hours B, FITC + live MV4–11 cells at 18 hours C, Annexin V positive cells at 48 hours D, FITC + MV4–11 cells at 48 hours for A192 and α-CD99-A192 treated T cells cocultured with leukemic MV4–11 cells at an E:T ratio of 5:1. Co-culture assays showed E, greater apoptosis in MV4–11 cells at 18 hours, but no significant apoptosis in MV4–11 cells at 48 hours and F, a reduction in viable leukemic cells at 18 and 48 hours in α-CD99-A192 treated T cells cocultured with leukemic MV4–11 cells at an E:T ratio of 5:1 compared with control. Flow cytometry panels showing Annexin V positive FITC − T cells G , 18 hours and H , 48 hours. I , Co-culture assays showed no significant toxicity to T cells at 18 hours and 48 hours. Luciferase assay also exhibited a reduction in viable leukemic cells in α-CD99-A192 treated T cells cocultured with leukemic J, MV4–11 cells, K, THP-1 and L, MOLM-13 cells at an E:T ratio of 5:1 compared with control. The differences between the groups were analyzed using unpaired t tests (***,P<0.001; **,P<0.01; *,P<0.05). The experiments were performed utilizing samples obtained from three donors.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Enhanced T cell activation and cytotoxicity against AML via targeted anti-CD99 nanoparticle treatment

doi: 10.1016/j.biopha.2024.117265

Figure Lengend Snippet: α-CD99-A192 treated T cells show increased cytotoxicity against leukemic cells. Flow cytometry panels showing. A, Annexin V positive cells at 18 hours B, FITC + live MV4–11 cells at 18 hours C, Annexin V positive cells at 48 hours D, FITC + MV4–11 cells at 48 hours for A192 and α-CD99-A192 treated T cells cocultured with leukemic MV4–11 cells at an E:T ratio of 5:1. Co-culture assays showed E, greater apoptosis in MV4–11 cells at 18 hours, but no significant apoptosis in MV4–11 cells at 48 hours and F, a reduction in viable leukemic cells at 18 and 48 hours in α-CD99-A192 treated T cells cocultured with leukemic MV4–11 cells at an E:T ratio of 5:1 compared with control. Flow cytometry panels showing Annexin V positive FITC − T cells G , 18 hours and H , 48 hours. I , Co-culture assays showed no significant toxicity to T cells at 18 hours and 48 hours. Luciferase assay also exhibited a reduction in viable leukemic cells in α-CD99-A192 treated T cells cocultured with leukemic J, MV4–11 cells, K, THP-1 and L, MOLM-13 cells at an E:T ratio of 5:1 compared with control. The differences between the groups were analyzed using unpaired t tests (***,P<0.001; **,P<0.01; *,P<0.05). The experiments were performed utilizing samples obtained from three donors.

Article Snippet: Anti-Human CD3 PerCP-Cyanine 5.5 (Clone: OKT3; eBioscience, Cat#45–0037–42), Anti-Human CD38 FITC (Clone: HB7; eBioscience, Cat#11–0388) and Anti-Human CD69 PE (Clone: FN50; eBioscience, Cat#12–0699) was added to the cells.

Techniques: Flow Cytometry, Co-Culture Assay, Control, Luciferase

Monkey ex - vivo -differentiated PC subset classification and differential expression analysis for PCs (A) Dot plot visualization of ex - vivo -differentiated PCs: subsets are listed on the y axis and genes (features) are listed along the x axis. Dot size represents the percentage of cells in a group expressing each gene; dot color indicates the normalized mean expression level in a group. (B) Heatmap showing expression of representative genes of PC markers ( CD38 , JCHAIN , XBP1 ) and proliferating marker ( MKI67 ). (C) Cluster renamed to B cell subsets based on the gene features from (A) and (B).

Journal: Cell Reports Methods

Article Title: Generation, expansion, gene delivery, and single-cell profiling in rhesus macaque plasma B cells

doi: 10.1016/j.crmeth.2024.100878

Figure Lengend Snippet: Monkey ex - vivo -differentiated PC subset classification and differential expression analysis for PCs (A) Dot plot visualization of ex - vivo -differentiated PCs: subsets are listed on the y axis and genes (features) are listed along the x axis. Dot size represents the percentage of cells in a group expressing each gene; dot color indicates the normalized mean expression level in a group. (B) Heatmap showing expression of representative genes of PC markers ( CD38 , JCHAIN , XBP1 ) and proliferating marker ( MKI67 ). (C) Cluster renamed to B cell subsets based on the gene features from (A) and (B).

Article Snippet: anti-CD38 FITC clone: OKT10 , Caprico Biotechnologies , 100815.

Techniques: Ex Vivo, Expressing, Marker

Using flow cytometry to validate non-canonical markers for NHP PCs (A) Flow plot of canonical PC markers (CD38, CD138) and IgG versus non-canonical markers. (B) IgG, CD59, and CD79A expression in CD38 − CD138 − B cells versus CD38 + CD138 + PCs. CD59 and CD38 were stained prior to fixation, while CD138, CD79A, and IgG were stained after fixation.

Journal: Cell Reports Methods

Article Title: Generation, expansion, gene delivery, and single-cell profiling in rhesus macaque plasma B cells

doi: 10.1016/j.crmeth.2024.100878

Figure Lengend Snippet: Using flow cytometry to validate non-canonical markers for NHP PCs (A) Flow plot of canonical PC markers (CD38, CD138) and IgG versus non-canonical markers. (B) IgG, CD59, and CD79A expression in CD38 − CD138 − B cells versus CD38 + CD138 + PCs. CD59 and CD38 were stained prior to fixation, while CD138, CD79A, and IgG were stained after fixation.

Article Snippet: anti-CD38 FITC clone: OKT10 , Caprico Biotechnologies , 100815.

Techniques: Flow Cytometry, Expressing, Staining

Comparison of human and monkey PC makers by scRNA-seq analysis (A) Ex - vivo -differentiated human PCs with CITE-seq. Classification of B cell subsets categorized by the indicated protein markers: IgM hi CD38 lo (activated B cells, ActB), IgM lo CD38 lo (pre-PBs), CD38 hi CD138 lo (PBs), and CD38 hi CD138 hi (PCs). B cell subsets and isotype are superimposed onto UMAP; day 13 B cells ( n = 2,897) are from two biological replicates. (B) Violin plot of indicated genes. (C) Dot plot visualization of ex - vivo -differentiated human PC: subsets are listed on the y axis and representative genes from <xref ref-type=Figure 3 D are listed along the x axis. (D) Schematic cartoon summary of human PC markers compared with monkey PC markers from scRNA analysis. ∗MHC class I is expressed in most cell types but is not ideal as a marker for NHP PCs. " width="100%" height="100%">

Journal: Cell Reports Methods

Article Title: Generation, expansion, gene delivery, and single-cell profiling in rhesus macaque plasma B cells

doi: 10.1016/j.crmeth.2024.100878

Figure Lengend Snippet: Comparison of human and monkey PC makers by scRNA-seq analysis (A) Ex - vivo -differentiated human PCs with CITE-seq. Classification of B cell subsets categorized by the indicated protein markers: IgM hi CD38 lo (activated B cells, ActB), IgM lo CD38 lo (pre-PBs), CD38 hi CD138 lo (PBs), and CD38 hi CD138 hi (PCs). B cell subsets and isotype are superimposed onto UMAP; day 13 B cells ( n = 2,897) are from two biological replicates. (B) Violin plot of indicated genes. (C) Dot plot visualization of ex - vivo -differentiated human PC: subsets are listed on the y axis and representative genes from Figure 3 D are listed along the x axis. (D) Schematic cartoon summary of human PC markers compared with monkey PC markers from scRNA analysis. ∗MHC class I is expressed in most cell types but is not ideal as a marker for NHP PCs.

Article Snippet: anti-CD38 FITC clone: OKT10 , Caprico Biotechnologies , 100815.

Techniques: Comparison, Ex Vivo, Marker

Journal: Cell Reports Methods

Article Title: Generation, expansion, gene delivery, and single-cell profiling in rhesus macaque plasma B cells

doi: 10.1016/j.crmeth.2024.100878

Figure Lengend Snippet:

Article Snippet: anti-CD38 FITC clone: OKT10 , Caprico Biotechnologies , 100815.

Techniques: Enzyme-linked Immunospot, Isolation, Enzyme-linked Immunosorbent Assay, Recombinant, Software